Reactive dose escalation of infliximab in patients with Crohn's disease in TAILORIX leads to improved outcomes

被引：0
|
作者：
Dreesen, E. [1 ]
Laharie, D. [2 ]
Lambrecht, G. [3 ]
Bossuyt, P. [4 ]
Buisson, A. [5 ]
Filippi, J. [6 ]
Van Hootegem, P. [7 ]
D'Haens, G. [8 ]
Vermeire, S. [9 ,10 ]
Gils, A. [1 ]
机构：
[1] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
[2] Hosp Haut Leveque, Bordeaux, France
[3] Damiaan Hosp, Oostende, Belgium
[4] Imelda Hosp, Bonheiden, Belgium
[5] Hosp Estaing, Clermont Ferrand, France
[6] Hosp Archet, Nice, France
[7] Sint Lucas Hosp, Brugge, Belgium
[8] Acad Med Ctr, Amsterdam, Netherlands
[9] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[10] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P572
引用
收藏
页码：S396 / S397
页数：3
相关论文
共 50 条
  • [1] REACTIVE DOSE ESCALATION OF INFLIXIMAB IN PATIENTS WITH CROHN'S DISEASE IN TAILORIX LEADS TO IMPROVED OUTCOMES
    Dreesen, Erwin
    Laharie, David
    Lambrecht, Guy
    Bossuyt, Peter
    Buisson, Anthony
    Filippi, Jerome
    Van Hootegem, Philippe
    D'Haens, Geert R.
    Vermeire, Severine
    Gils, Ann
    GASTROENTEROLOGY, 2018, 154 (06) : S823 - S824
  • [2] Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease
    Sako, M.
    Kawaguchi, T.
    Hirayama, A.
    Fukushi, G.
    Hayama, K.
    Fujiwara, T.
    Yoshimura, N.
    Takazoe, M.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S231 - S231
  • [3] Time of infliximab therapy initiation and dose escalation in Crohn's disease
    Mindy CW Lam
    Terry Lee
    Kenneth Atkinson
    Brian Bressler
    World Journal of Gastroenterology, 2014, (01) : 214 - 218
  • [4] Time of infliximab therapy initiation and dose escalation in Crohn's disease
    Lam, Mindy C. W.
    Lee, Terry
    Atkinson, Kenneth
    Bressler, Brian
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (01) : 214 - 218
  • [5] Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn's disease: pharmacokinetic-pharmacodynamic analysis of TAILORIX
    Dreesen, E.
    D'Haens, G.
    Baert, F.
    Pariente, B.
    Bouhnik, Y.
    vander Woude, J.
    Moreau, J.
    Laharie, D.
    Vermeire, S.
    Gils, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S63 - S64
  • [6] INFLIXIMAB EXPOSURE PREDICTS SUPERIOR ENDOSCOPIC OUTCOMES IN PATIENTS WITH ACTIVE CROHN'S DISEASE: PHARMACOKINETIC-PHARMACODYNAMIC ANALYSIS OF TAILORIX
    Dreesen, Erwin
    D'Haens, Geert R.
    Baert, Filip J.
    Pariente, Benjamin
    Bouhnik, Yoram
    Van der Woude, Christien Janneke
    Moreau, Jacques
    Laharie, David
    Vermeire, Severine
    Gils, Ann
    GASTROENTEROLOGY, 2018, 154 (06) : S821 - S821
  • [7] RISANKIZUMAB DOSE ESCALATION IN PATIENTS WITH CROHN'S DISEASE
    Nichols, Patrick
    Kozlicki, Miranda
    Fann, Jessica
    Zuckerman, Autumn
    Dalal, Robin
    GASTROENTEROLOGY, 2024, 166 (03) : S123 - S123
  • [8] RISANKIZUMAB DOSE ESCALATION IN PATIENTS WITH CROHN'S DISEASE
    Nichols, Patrick
    Kozlicki, Miranda
    Fann, Jessica
    Zuckerman, Autumn
    Dalal, Robin
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S88 - S89
  • [9] Risankizumab dose escalation in patients with Crohn's disease
    Zuckerman, Autumn
    Nichols, Patrick
    Fann, Jessica
    Kozlicki, Miranda
    Dalal, Robin
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 : S8 - S9
  • [10] Infliximab dose intensification in patients with Crohn's disease
    Nature Clinical Practice Gastroenterology & Hepatology, 2007, 4 (11): : 588 - 589
12345